I am bringing an economic, environmental, and green chemistry application today: Desulfurization of biodiesel produced from waste fats, oils, and grease using β-CD by Cong Liu, Anthony Provatas and Richard Parnas from the University of Connecticut.
Great learning opportunity presented by Ajay Semalty on CD complexes in general. Here you can learn about CD chemistry and basic properties and techniques to make complexes, and analyze them shown in several practical examples. Extremely informative!
Please share and spread the word.
Easy to digest review on drug delivery of CD-based nanoparticles for the delivery of tyrosine kinase inhibitors and the synthesis methods of cyclodextrin-based compounds.
Greennanotech kft, Nanoscitec_gmbh, NanoSciTech GmbH
New kid on the block: Asterivir’s website has just gone live. Asterivir – a spinout from EPFL (École Polytechnique fédérale de Lausanne) – develops CD-based broad spectrum antivirals lead by Francesco Stellacci, Paulo Jacob Silva and Oscar Buset. The initial findings of the company were published earlier (Caroline Tapparel Vu et al. )
The website contains nice video graphics of the mechanism of action, which is worth checking!
Fresh from the oven of the Francesco Trotta and Adrián Matencio Durán (Università degli Studi di Torino) lab, two papers on the uses of hyper-branched CD-polymer:
No 1: use as an anticoagulant, which is a very innovative application for CDs that are getting more and more spotlight
No 2: use as transfection promoters of plasmids.
I congratulate you on this ambitious research goal, loved both papers and look forward to seeing from sprouting from the collaboration you recently started with CarboHyde!
Yousef Khazaei monfared, Mohammad Mahmoudian, Claudio Cecone, Fabrizio Caldera, Sanya Haiaty, Reza Rahbarghazi, Parvin Zakeri-Milani, Gjylije Hoti, Fabrizio Caldera, Roberta Cavalli
Great overview of CD-based drug delivery systems for cancer therapy from Carol Davila University of Medicine and Pharmacy and University POLITEHNICA of Bucharest
Monica Alexandra Bolocan, Octavian Andronic, Alexandru Mihai Grumezescu, Rodica Birla
This novel application is a fascinating combination of tumor targeting and diagnosis using of 68Ga-labelled cyclodextrin for positron emission tomography of PGE2-positive tumors.
University of Debrecen – Gabor Opposits, István Jószai, Istvan Kertesz, Zita Képes, Méhes Gábor, Ferenc Fenyvesi István Hajdu, György Trencsenyi
Topical drug delivery with CDs seems straightforward, even with the extra advantage that CDs can contribute not only as solubilizers but also as permeation enhancers. Still, despite cosmetics, very few products are on the market.
The nano gel concept by Università degli Studi di Firenze (Marzia Cirri, Giulia Nerli, Natascia Mennini, Francesca Maestrelli, and Paola Mura) may open some new doors in this area.
Even though used in many formulations with CDs, new ones entering clinical trials are not often. Midatech Pharma PLC recently announced recruiting the first patient in the Phase 1 Study of MTX-110 for recurrent #glioblastoma (NCT 05324501). Midatech has previously reported encouraging results from a Phase I study of MTX110 in diffuse intrinsic pontine glioma (NCT03566199, NCT04264143), and a Phase I study of MTX110 in medulloblastoma is being undertaken. and recurrent medulloblastoma (NCT04315064).
MTX110 is a water-soluble form of a panobinostat-free base, achieved through complexation with hydroxypropyl-β-cyclodextrin (HPBCD), that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumor. Panobinostat is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). The currently available oral formulation of panobinostat lactate (Farydak®) is not suitable for the treatment of brain cancers owing to poor blood-brain barrier penetration and inadequate brain drug concentrations.
MTX110 is delivered directly into and around the patient’s tumor via a catheter system (e.g., CED or fourth ventricle infusions) to bypass the blood-brain barrier. This technique exposes the tumor to very high drug concentrations while simultaneously minimizing systemic drug levels and the potential for toxicity and other side effects.
MTX110 has been granted Orphan Drug and Fast Track designations by the FDA and Orphan Medicinal Product designation by EMA.
Using CDs in enantioseparation is rather straightforward. On an analytical level. However, preparation is a completely different question. Potential solutions for this problem and the impact of CD types are explored in the study of Zhejiang University of Technology and Jiaxing University, discussing applications in CPC and liquid-liquid extraction.